Fight Illicit Pill Presses Act

The Fight Illicit Pill Presses Act was introduced on September 18, 2025 by Senator Cornyn (R-TX) and 13 cosponsors. It is currently in the earliest legislative stage — referred to the Senate Judiciary Committee, with no hearings or markup. A companion bill (H.R. 5880) exists in the House, but both are essentially fledgling proposals with zero legislative velocity since introduction. The bill does not authorize or appropriate any federal funds. It amends the Controlled Substances Act to require that anyone manufacturing, distributing, or selling tableting machines, encapsulating machines, or their critical components (upper punches, lower punches, dies) maintain records and identify each machine by serial number. This is purely a regulatory paperwork expansion — no grants, no tax credits, no direct procurement. Structural winners and losers: There are no pure-play public companies that derive primary revenue from pill press manufacturing. The diversified industrial manufacturer most likely to touch this equipment is Illinois Tool Works ($ITW), which operates dozens of specialty industrial units. However, pill press machinery is a tiny fraction of ITW's business. No other publicly traded US company is directly affected. Increased DEA compliance costs will be negligible even for small private manufacturers. Market data shows $ITW at $258.92 as of April 30, 2026, down 3.85% over the past 7 days. However, this decline is attributable to broader market conditions — the stock is within its 52-week range of $236.68—$303.16. There is no credible basis to link ITW's recent price movement to S. 2870. Legislative timeline: The bill has been dormant for over 7 months. No committee action, no amendments, no markups. Given the early stage, lack of funding, and the 119th Congress now in its second session, passage probability is low unless the bill gains significant sponsorship momentum. Even if passed eventually, the financial impact on public markets would remain negligible.